A study of the role of the myocyte-specific enhancer factor-2A gene in coronary artery disease


      We evaluated the role of the MEF2A as a risk factor for coronary artery disease (CAD) in 1186 subjects with angiographically documented disease compared with 885 CAD-free individuals in the Saudi population. Screening the gene revealed exon 11 as the most polymorphic of all coding regions, harbouring several substitution polymorphisms and insertion/deletions (indels) at a locus containing an 11 CAG trinucleotide chain and a CCGCCGCCA sequence, which introduced frameshifts and premature stop codons at nt146637 and nt146647, nt146780 or nt146783. While these indels were not significantly associated with CAD, a causative relationship was established for rs1059759 G>C [1.21(1.02–1.43); p = 0.029], and a borderline one for rs34851361 A>G [1.22(0.9–1.54); p = 0.088]. Importantly, a haplotype 1A-2G-3G-4A-5C-6G-7G-8A constructed from the studied SNPs was also associated with CAD [6.39(0.93–43.75); p = 0.0052]. These results identify MEF2A gene as a susceptibility gene for CAD.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Molkentin J.D.
        • Black B.L.
        • Martin J.F.
        • Olson E.N.
        Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins.
        Cell. 1995; 83: 1125-1136
        • Cripps R.M.
        • Black B.L.
        • Zhao B.
        • et al.
        The myogenic regulatory gene Mef2 is a direct target for transcriptional activation by Twist during Drosophila myogenesis.
        Genes Dev. 1998; 12: 422-434
        • Gregoire S.
        • Xiao L.
        • Nie J.
        • et al.
        Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2.
        Mol Cell Biol. 2007; 27: 1280-1295
        • Zhang C.L.
        • McKinsey T.A.
        • Olson E.N.
        The transcriptional corepressor MITR is a signal-responsive inhibitor of myogenesis.
        Proc Natl Acad Sci USA. 2001; 98: 7354-7359
        • Yuan H.
        • Lu H.W.
        • Hu J.
        • et al.
        MEF2A gene and susceptibility to coronary artery disease in the Chinese people.
        Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006; 31: 453-457
        • Gonzalez P.
        • Garcia-Castro M.
        • Reguero J.R.
        • et al.
        The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction.
        J Med Genet. 2006; 43: 167-169
        • Bhagavatula M.R.
        • Fan C.
        • Shen G.Q.
        • et al.
        Transcription factor MEF2A mutations in patients with coronary artery disease.
        Hum Mol Genet. 2004; 13: 3181-3188
        • Wang L.
        • Fan C.
        • Topol S.E.
        • Topol E.J.
        • Wang Q.
        Mutation of MEF2A in an inherited disorder with features of coronary artery disease.
        Science. 2003; 302: 1578-1581
        • Altshuler D.
        • Hirschhorn J.N.
        MEF2A sequence variants and coronary artery disease: a change of heart?.
        J Clin Invest. 2005; 115: 831-833
        • Weng L.
        • Kavaslar N.
        • Ustaszewska A.
        • et al.
        Lack of MEF2A mutations in coronary artery disease.
        J Clin Invest. 2005; 115: 1016-1020
        • Hsu L.A.
        • Chang C.J.
        • Teng M.S.
        • et al.
        CAG repeat polymorphism of the MEF2A gene is not associated with the risk of coronary artery disease among Taiwanese.
        Clin Appl Thromb Hemost. 2009; (Jan 19; Epub ahead of print)
        • Gulec S.
        • Ruchan Akar A.
        • Akar N.
        MEF2A sequence variants in Turkish population.
        Clin Appl Thromb Hemost. 2008; 14: 465-467
        • Lieb W.
        • Mayer B.
        • Konig I.R.
        • et al.
        Lack of association between the MEF2A gene and myocardial infarction.
        Circulation. 2008; 117: 185-191
        • Kajimoto K.
        • Shioji K.
        • Tago N.
        • et al.
        Assessment of MEF2A mutations in myocardial infarction in Japanese patients.
        Circ J. 2005; 69: 1192-1195
        • Horan P.G.
        • Allen A.R.
        • Hughes A.E.
        • et al.
        Lack of MEF2A Delta7aa mutation in Irish families with early onset ischaemic heart disease, a family based study.
        BMC Med Genet. 2006; 7: 65
        • Schaid D.J.
        • Rowland C.M.
        • Tines D.E.
        • Jacobson R.M.
        • Poland G.A.
        Score tests for association between traits and haplotypes when linkage phase is ambiguous.
        Am J Hum Genet. 2002; 70: 425-434
        • Lake S.L.
        • Lyon H.
        • Tantisira K.
        • et al.
        Estimation and tests of haplotype–environment interaction when linkage phase is ambiguous.
        Hum Hered. 2003; 55: 56-65
        • Black B.L.
        • Lu J.
        • Olson E.N.
        The MEF2A 3′ untranslated region functions as a cis-acting translational repressor.
        Mol Cell Biol. 1997; 17: 2756-2763